Canakinumab is a recombinant, human anti-human-IL-1ฮฒ monoclonal antibody that belongs to the IgG1/ฮบ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain ...
Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients โฅ4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinum...
Centro de Investigaciones Clinicas del Litoral, Santa Fe, Argentina
Clinica Chiclayo, Chiclayo, Peru
King George Hospital, Visakhapatnam, India
Novartis Investigative Site, Oxford, United Kingdom
University of Louisville, Louisville, Kentucky, United States
Tufts Medical Center, Boston, Massachusetts, United States
Novartis Investigative Site, Izmir, Turkey
St. Barnabas Ambulatory Care Center, Livingston, New Jersey, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Arkansas Children's Hospital Research Inst, Little Rock, Arkansas, United States
Talbert Medical Group, Huntington Beach, California, United States
Health Awareness, Jupiter, Florida, United States
East-West Medical Research institute, Honolulu, Hawaii, United States
Montana Medical Research, Missoula, Montana, United States
Northwest Clinical Trials, Boise, Idaho, United States
Novartis Investigative Site, Wellingborough, United Kingdom
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 9, Bethesda, Maryland, United States
Novartis Investigator Site, Geneva, Switzerland
Allied Research International - Cetero Research Miami, Miami, Florida, United States
Elite Research Institute Miami, Miami, Florida, United States
Novartis Investigative Site, St. Petersberg, Russian Federation
Novartis Investigator Site, Richmond, Virginia, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.